epirubicin has been researched along with Adrenocortical Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bechter, OE; Bronswijk, MJH; Laenen, A | 1 |
| Caron, P; Grunenwald, S | 1 |
2 other study(ies) available for epirubicin and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Mitotane; Retrospective Studies; Taxoids; Treatment Outcome | 2020 |
[Adrenocortical carcinomas: therapeutic advances in 2011].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Humans; Mitotane; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2011 |